MapLight Therapeutics, Inc. (MPLT) - Q1 2026 10-Q Summary
Business Context and Reporting Period
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders. This report covers the quarterly period ended March 31, 2026. The company recently completed its Initial Public Offering (IPO) in October 2025 and is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(60.7) million | $(22.3) million |
| Operating Expenses | $64.5 million | $23.5 million |
| Research & Development (R&D) | $53.7 million | $19.8 million |
| General & Administrative (G&A) | $10.8 million | $3.8 million |
| Cash, Cash Equivalents & Investments | $395.2 million | $50.4 million (Cash only) |
| Accumulated Deficit | $(421.2) million | $(221.7) million |
| Net Cash Used in Operating Activities | $(51.2) million | $(25.6) million |
Material Changes vs. Prior Period
- Expense Surge: Total operating expenses increased by $41.0 million (174%) compared to Q1 2025. This is primarily driven by the advancement of clinical trials and increased headcount following the IPO.
- R&D Increase: R&D expenses rose $33.9 million, with a $22.9 million increase in clinical trial expenses and an $8.9 million increase in employee-related costs (including a $5.3 million increase in stock-based compensation).
- G&A Increase: G&A expenses increased $7.1 million, largely due to higher employee-related costs ($4.9 million) and professional fees associated with public company compliance ($2.1 million).
- Liquidity Position: Cash and investments grew significantly to $395.2 million as of March 31, 2026, compared to $46.9 million in cash equivalents at the start of the period, reflecting the October 2025 IPO proceeds ($261.6 million net) and concurrent private placement ($7.5 million net).
Outlook, Guidance, and Risks
- Clinical Milestones:
- ML-007C-MA (Schizophrenia/ADP): Enrollment for the Phase 2 ZEPHYR trial (schizophrenia) is complete (307 participants); topline results expected mid-August 2026. The Phase 2 VISTA trial (ADP) is ongoing; topline results expected H2 2027. Received FDA Fast Track designation for ADP in December 2025.
- ML-004 (ASD): Phase 2 IRIS trial randomized 161 participants; topline results expected mid-August 2026.
- Liquidity Outlook: Management believes existing cash, cash equivalents, and investments ($395.2 million) are sufficient to fund operations through 2027.
- Capital Needs: The company expects to continue incurring significant losses and will require substantial additional financing to complete development and commercialization. Future funding may come from equity offerings, debt, or collaborations.
- Risks: Key risks include the inherent uncertainty of clinical trial outcomes, potential regulatory delays (including previous clinical holds on ML-007C-MA and ML-004 which were lifted), reliance on third-party manufacturers, and the need to raise additional capital which may result in dilution.
Investor Verification Checklist
- Verify the timeline and enrollment status of the ZEPHYR and IRIS Phase 2 trials, given the expectation of topline results in August 2026.
- Monitor the burn rate relative to the $395.2 million cash runway to confirm the "through 2027" liquidity estimate remains valid.
- Review the composition of the $339.5 million in investments (short-term and long-term) for unrealized losses and liquidity constraints.
- Assess the impact of the October 2025 reverse stock split (1-for-16.8) on share count and per-share metrics.
- Track potential future milestone payments under the NeuroSolis asset purchase agreement and Vanderbilt University license agreement.